ABSTRACT
The coronavirus has spread fast resulting in a worldwide pandemic. Early discovery of positive patients is critical in preventing the pandemic from spreading further, leading to the development of diagnostic technologies that provide rapid and reliable responses for COVID-19 detection. Previous research has shown that chest x-rays are an essential tool for the detection and diagnosis of sirivanoroC (COVID-19) patients. A radiological finding known as ground-glass opacity (GGO), which causes color and texture changes, was discovered in the lung of a person with COVID-19 as a consequence of x-ray tests. An automatic method to assist radiologists is required due to the carelessness of radiologists who work a long time and misdiagnosis resulting in the confusion of findings with different diseases, in this study, were described a new technique to help us with the early diagnosis of COVID-19 using x-rays that is based on fuzzy classification. The skewness, kurtosis, and average statistical features of x-rays of patients in two classes, COVID and Normal, are calculated in the suggested method, and the value ranges for both classes are identified. In the building of a fuzzy logic classifier, three statistical characteristics and value ranges are used as membership functions. The suggested solution, which uses a user-friendly interface, allows for quick and accurate COVID vs Normal (binary classification). Experiments show that our method has a lot of promise for radiologists to validate their initial screening and enhance early diagnosis, isolation, and therapy, which helps prevent infection and contain the pandemic. © 2023 Author(s).
ABSTRACT
Since early December 2019, the coronavirus disease 2019 (COVID-19) has been relentlessly spread worldwide and has hit the healthcare systems with terrible force. Pharmacists play a vital role in the healthcare system in providing medicines, therapeutics, vaccines, clinical services, and other pharmaceutical care services to patients. Therefore, to ensure all these services continued at King Abdulaziz Medical City - Jeddah during the COVID-19 pandemic, the Department of Pharmaceutical Care initiated a departmental crisis preparedness plan, as a part of general hospital preparedness plan. It started with adjusting medication dosing time, instituting a daily medication refill process, working remotely, expanding the use of automation, and modifying employee schedules. Other actions included the following: handling drug shortages, placing restrictions on some medications, using personal protective equipment, changing routine practices of pharmacy aides, revising the medication delivery process, starting a contingency training program, and restricting pneumatic tube operation. We took guidance from the Ministry of Health, our own institute's experience, World Health Organization recommendations, updated scientific research, and the American Society of Health-System Pharmacists regulatory updates. This article aims to describe how health services, policies, and systems were applied and adapted to address a specific problem while maintaining all pharmacy employees' safety. This article reviews the inpatient pharmacy's particular needs and responses to these needs to meet the COVID-19 pandemic challenges.
ABSTRACT
Objectives: To describe the clinical characteristics and angiographic features of COVID-19 patients presenting with acute coronary syndrome (ACS) and to compare with non-COVID-19 ACS patients presenting simultaneously. Methodology: In a case control design, data were extracted from a prospectively collected COVID-19 and NCDR registry. All ACS patients who underwent cardiac catheterization from April 2020 to May 2021 were included. All of the patients were taken to the Cath lab for diagnostic coronary angiography and possible percutaneous intervention. Demographic and clinical characteristics, angiographic features, and in-hospital outcomes were compared between ACS patients with and without COVID-19. Results: A total of 4027 COVID-19 negative patients, and 80 COVID-19 positive were included. Total of 83% in COVID-19 and 88% in non-COVID-19 group had ST elevation myocardial infarction. Majority of the COVID-19 positive patients had sub-optimal TIMI flow grade (<III) post procedure and had a high thrombus burden (11.2% vs. 2.9%;p<0.001). Majority of the patients who had COVID-19 and ACS required mechanical circulatory support (48.8% vs. 0.3%;p<0.001). The mortality rates were also higher in COVID-19 positive group (38.8% vs. 1.3%;p<0.001). Among the COVID-19 positive patients 66.3% (53) had high thrombus burden (≥4 grade), intervention was performed in 73.7% (59). Post-intervention myocardial blush grade ≤2 was observed in 57.6% (34), slow flow in 85.3% (29), and phasic flow possibly due to elevated LVEDP in 41.2% (14) patients. Conclusion: COVID-19 patients with ACS had a higher severity of illness at presentation and worse outcomes as compared to simultaneously presenting non-COVID patients. © 2023 The authors.
ABSTRACT
Background: Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce. This study aims to evaluate the effectiveness and safety of oseltamivir in critically ill patients with COVID-19. Methods: This multicenter, retrospective cohort study includes critically ill adult patients with COVID-19 admitted to the intensive care unit (ICU). Patients were categorized into two groups based on oseltamivir use within 48 hours of ICU admission (Oseltamivir vs. Control). The primary endpoint was viral load clearance. Results: A total of 226 patients were matched into two groups based on their propensity score. The time to COVID-19 viral load clearance was shorter in patients who received oseltamivir (11 vs. 16 days, p = 0.042; beta coefficient: -0.84, 95%CI: (-1.33, 0.34), p = 0.0009). Mechanical ventilation (MV) duration was also shorter in patients who received oseltamivir (6.5 vs. 8.5 days, p = 0.02; beta coefficient: -0.27, 95% CI: [-0.55,0.02], P = 0.06). In addition, patients who received oseltamivir had lower odds of hospital/ventilator-acquired pneumonia (OR:0.49, 95% CI:(0.283,0.861), p = 0.01). On the other hand, there were no significant differences between the groups in the 30-day and in-hospital mortality. Conclusion: Oseltamivir was associated with faster viral clearance and shorter MV duration without safety concerns in critically ill COVID-19 patients.
ABSTRACT
INTRODUCTION: The COVID-19 pandemic has had a significant impact on substance abuse patterns in recent times. Many people have experienced increased stress, anxiety, and social isolation, which has led to higher rates of substance abuse and addiction. It impacts on the orofacial region, particularly temporomandibular joint (TMJ). This review was undertaken to assess the association between substance abuse and temporomandibular disorders. (TMDs). MATERIALS AND METHODS: The databases of PubMed, Google Scholar, Web of Science and Cochrane were searched for articles based of set PECO criteria. A comprehensive search using keywords of "Psychoactive substances", "Illegal substances", "substance abuse", "narcotics", "temporomandibular joint" and "temporomandibular joint disorders" yielded a total of 1405 articles. Modified Newcastle-Ottawa Scale for observational studies assessed the risk of bias of included studies. RESULTS: Two studies were reviewed. Samples recruited were either from rehabilitation centres or prisoners and fell in the second to fourth decade. A definite association was noted between psychoactive substance and TMDs. Moderate to low risk of bias was noted in all the studies evaluated. CONCLUSION: Further research is needed to better understand the nature of this relationship and the underlying mechanisms involved. It is important for healthcare providers to be aware of this potential association and to screen for substance abuse in patients with TMD symptoms.
ABSTRACT
The objective of this article is to study the impact of COVID-19 on the lives of women by exploring different aspects like their daily work patterns, hygiene practices, psychological effects and nutritional status during the pandemic. 510 women participated in the online survey. The majority of the respondents belonged to the age group of 20-29 years and were either graduates or above. 37.3% of the working respondents reported increased professional responsibilities during the pandemic. Cooking and cleaning occupied most of the time during the lockdown. Anxiety, lack of concentration and frequent arguments with the family members were reported by the respondents. Many of the respondents took up physical activities to maintain their fitness. They also believed that usage of masks would prevent them from catching the infection. 75.2% of women included vitamin-rich sources in their diet. This level of consciousness might be linked to the educational profile of the respondents.
ABSTRACT
The purpose of this study is to investigate how artificial intelligence can mitigate unknown-unknown risks, taking COVID-19 as a case. The utilization of this technology has helped with the risk management and mitigations process by providing efficient solutions. Today, the artificial intelligence of applications plays a critical role in containing the fast spread of COVID-19 virus and reducing the number of infected individuals. This research will explore how countries around the world have benefited from contact tracing applications. The research discussed the UAE Alhosn application compared to the applications developed by China, Australia, Thailand, France, South Korea to identify the best features and better utilization of AI technology in the applications. In addition, a mixed-method approach used in this research, and a combination of a qualitative and a quantitative approach to make a clear understanding of the topic and find out accurate results. For qualitative research, interviews were conducted with five people from different companies in the UAE. For quantitative research, ten questions survey was sent to a sample of 50 random respondents who are the users of Alhosn application. Domain analysis was used to organize the ideas and to generate other ideas. The research will also gather secondary data based on reviews of literature related to the research topic. Based on the gathered information and research results recommendations were given. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.
ABSTRACT
(1) Background: COVID-19 caused the worst international public health crisis, accompanied by major global economic downturns and mass-scale job losses, which impacted the psychosocial wellbeing of the worldwide population, including Saudi Arabia. Evidence of the high-risk groups impacted by the pandemic has been non-existent in Saudi Arabia. Therefore, this study examined factors associated with psychosocial distress, fear of COVID-19 and coping strategies among the general population in Saudi Arabia. (2) Methods: A cross-sectional study was conducted in healthcare and community settings in the Saudi Arabia using an anonymous online questionnaire. The Kessler Psychological Distress Scale (K-10), Fear of COVID-19 Scale (FCV-19S) and Brief Resilient Coping Scale (BRCS) were used to assess psychological distress, fear and coping strategies, respectively. Multivariate logistic regressions were used, and an Adjusted Odds Ratio (AOR) with 95% Confidence Intervals (CIs) was reported. (3) Results: Among 803 participants, 70% (n = 556) were females, and the median age was 27 years; 35% (n = 278) were frontline or essential service workers; and 24% (n = 195) reported comorbid conditions including mental health illness. Of the respondents, 175 (21.8%) and 207 (25.8%) reported high and very high psychological distress, respectively. Factors associated with moderate to high levels of psychological distress were: youth, females, non-Saudi nationals, those experiencing a change in employment or a negative financial impact, having comorbidities, and current smoking. A high level of fear was reported by 89 participants (11.1%), and this was associated with being ex-smokers (3.72, 1.14-12.14, 0.029) and changes in employment (3.42, 1.91-6.11, 0.000). A high resilience was reported by 115 participants (14.3%), and 333 participants (41.5%) had medium resilience. Financial impact and contact with known/suspected cases (1.63, 1.12-2.38, 0.011) were associated with low, medium, to high resilient coping. (4) Conclusions: People in Saudi Arabia were at a higher risk of psychosocial distress along with medium-high resilience during the COVID-19 pandemic, warranting urgent attention from healthcare providers and policymakers to provide specific mental health support strategies for their current wellbeing and to avoid a post-pandemic mental health crisis.
ABSTRACT
The COVID-19 epidemic has affected not only people's daily lives but also the working methods of clinicians, surgical procedures, open/minimally invasive procedures, operating room management, patient and healthcare worker safety, education and training. The main objective of this study was to review selected articles and determine the changes in the general surgery protocols/procedures before and after the emergence of the COVID-19 pandemic. The literature was carried out in PubMed-Medline, Cochrane Library, Embase, Scopus and Google Scholar. The terms utilised for the searches were "SARS-CoV-2”, "Surgery”, "COVID-19”, "Surgical protocol”, "Surgical recommendations” and "before and after”. A total of 236 studies were identified, out of which 41 studies were included for data extraction. Significant changes in all the articles were observed with respect to the surgeries done before, during and after the COVID-19 pandemic. Specifically, the number of elective surgeries were considerably fewer in comparison to the pre-pandemic period. Since the COVID-19 pandemic started, hospitals all throughout the world have conducted significantly fewer procedures, particularly elective/non-urgent surgeries.
ABSTRACT
A dramatic increase in user and capacity demands has been noted after the COVID-19 pandemic. These challenges have damaged the 5G communication system mobility. Therefore, developing mobility and enhancing capacity transmission of 5G advanced services are the focused research gaps in the current era. In this paper, the free space optics (FSO) link is modeled with wavelength division multiplexing (WDM) technology based optical fiber system, purposing to enhance the 5G capabilities in multi-channel, high distance, and bidirectional transmissions. In addition, the presented hybrid FSO-WDM supported optical fiber network is analyzed for 4, 8, and 16 × 10 Gbps downlink and uplink transmission. The paper also includes the mathematical discussion of merged fiber length (SMF = 30 km) and FSO (600 m) with improved mobility management. In another contribution, the tolerance against Rayleigh backscattering (RB) noises is developed through various wavelengths of downlink and uplink channels. Finally, we perform the simulation analysis and reliability of the proposed structure for the 5G advanced communication system. © 2023 by the authors.
ABSTRACT
We identify diversification benefits among Asian equity markets in the COVID-19 era. We find that such benefits among Asia-Pacific markets changed considerably during the pandemic, and most changes were persistent. In most cases, any of the sample equities had at least one safe-haven protection. The exceptions are Pakistan, Thailand, and Singapore, where diversification benefits are limited and vary across subperiods. The Hong Kong equity market provides safe-haven protection to most markets during periods of extreme negative returns. Further, we find that greater (lower) weightings on the Bangladeshi, Taiwanese, and Malaysian (Thai) markets provide important diversification in terms of maximizing Sharpe ratio and minimizing variance during the pandemic. © 2023 Elsevier Inc.
ABSTRACT
Coronavirus disease (COVID-19) is a pandemic disease caused by SARS-COV-2 that primarily attacks the respiratory system of the host. This disease was first reported in early December 2019, and the World Health Organization (WHO) classified the ongoing COVID-19 outbreak as a pandemic disease-causing global public health emergency by mid-January 2020. The human-to-human transmission occurs by droplets, infected hands, or surfaces with an in-cubation time of 2-14 days. It displays signs and symptoms, and if the disease progresses, it leads to death. To avoid symptomatic symptoms or increase infection severity, early diagnosis, quarantine, and supportive care can help to cure the patient infected with COVID-19. Several attempts have been projected for the development of vaccines against COVID-19. As of July 2, 2021, 600 vaccine candidates worldwide were evaluated against SARS-CoV-2, of which 300 have reached the preclinical stage of their development. Presently, Moderna (mRNA-1273), Shenzhen Geno-Immune Medical Institute (LV-SMENP-DC), Shenzhen Geno-Immune Medical Institute (Pathogen specific APC), CanSino Biologicals (Ad5-nCoV), Inovio Pharmaceuti-cals (INO-4800) have plunged into the phase I/II clinical trials (Source: ClinicalTrials.gov web-site;WHO). Scientists are increasingly seeking a key hide behind pathogenic pathways, epide-miological features, and future drug goals, which will lead to the development of successful strategies for prevention and treatment. Based on the current published data, we summarize the structure, life cycle of SARS-CoV-2 and the various product categories available as anti-COVID-19 agents (antiviral), with special emphasis on Chinese herbal medicines, which were licensed as anti-COVID agents by the Chinese Government. Such knowledge can be used as guidelines for COVID-19 clinical therapy. © 2023 Bentham Science Publishers.
ABSTRACT
The COVID-19 epidemic has affected not only people's daily lives but also the working methods of clinicians, surgical procedures, open/minimally invasive procedures, operating room management, patient and healthcare worker safety, education and training. The main objective of this study was to review selected articles and determine the changes in the general surgery protocols/procedures before and after the emergence of the COVID-19 pandemic. The literature was carried out in PubMed-Medline, Cochrane Library, Embase, Scopus and Google Scholar. The terms utilised for the searches were "SARS-CoV-2", "Surgery", "COVID-19", "Surgical protocol", "Surgical recommendations" and "before and after". A total of 236 studies were identified, out of which 41 studies were included for data extraction. Significant changes in all the articles were observed with respect to the surgeries done before, during and after the COVID-19 pandemic. Specifically, the number of elective surgeries were considerably fewer in comparison to the pre-pandemic period. Since the COVID-19 pandemic started, hospitals all throughout the world have conducted significantly fewer procedures, particularly elective/non-urgent surgeries.
ABSTRACT
Atrial fibrillation (Afib) can contribute to a significant increase in mortality and morbidity in critically ill patients. Thus, our study aims to investigate the incidence and clinical outcomes associated with the new-onset Afib in critically ill patients with COVID-19. A multicenter, retrospective cohort study includes critically ill adult patients with COVID-19 admitted to the intensive care units (ICUs) from March, 2020 to July, 2021. Patients were categorized into two groups (new-onset Afib vs control). The primary outcome was the in-hospital mortality. Other outcomes were secondary, such as mechanical ventilation (MV) duration, 30-day mortality, ICU length of stay (LOS), hospital LOS, and complications during stay. After propensity score matching (3:1 ratio), 400 patients were included in the final analysis. Patients who developed new-onset Afib had higher odds of in-hospital mortality (OR 2.76; 95% CI: 1.49-5.11, P = .001). However, there was no significant differences in the 30-day mortality. The MV duration, ICU LOS, and hospital LOS were longer in patients who developed new-onset Afib (beta coefficient 0.52; 95% CI: 0.28-0.77; P < .0001,beta coefficient 0.29; 95% CI: 0.12-0.46; P < .001, and beta coefficient 0.35; 95% CI: 0.18-0.52; P < .0001; respectively). Moreover, the control group had significantly lower odds of major bleeding, liver injury, and respiratory failure that required MV. New-onset Afib is a common complication among critically ill patients with COVID-19 that might be associated with poor clinical outcomes; further studies are needed to confirm these findings.
Subject(s)
Atrial Fibrillation , COVID-19 , Adult , Humans , COVID-19/complications , Retrospective Studies , Atrial Fibrillation/complications , Atrial Fibrillation/epidemiology , Incidence , Critical Illness , Intensive Care Units , Hospital MortalityABSTRACT
The COVID-19 pandemic coincided with the growth and ripeness of several digital methods, such as Artificial Intelligence (AI) (including Machine Learning (ML) and Deep Learning (DL)), internet of things (IoT), big-data analytics, Software Defined Network (SDN), robotic technology, and blockchain, etc. resulting in an experience chance for telemedicine advancement. In several nations, a telemedicine platform based on digital technology has been built and integrated into the clinical workflow in a variety of modes, including many-To-one, one-To-many, consultation mode, and practical-operation modes. These platforms are practical, efficient, and successful for exchanging epidemiological data, facilitating face-To-face interactions between patients or healthcare professionals over long distances, lowering the risk of disease transmission, and enhancing patient outcomes. This article provides a Systematic Literature Review (SLR) to call attention to the most recent advancements in evaluating COVID-19 data utilizing various methodologies such as ML, DL, SDN, and IoT. The number of studies on ML and DL provided and reviewed in this article has proven a considerable effect on the prediction and spreading of COVID-19. The main goal of this study is to show how ML, DL, IoT, and SDN may be used by researchers to provide significant solutions for authorities and healthcare statements to lessen the influence of pestilence. This report also includes many novel strategies for raising the prevalent telemedicine use. © 2022 IEEE.
ABSTRACT
BACKGROUND: Previous studies have shown that non-critically ill COVID-19 patients co-infected with other respiratory viruses have poor clinical outcomes. However, limited studies focused on this co-infections in critically ill patients. This study aims to evaluate the clinical outcomes of critically ill patients infected with COVID-19 and co-infected by other respiratory viruses. METHODS: A multicenter retrospective cohort study was conducted for all adult patients with COVID-19 who were hospitalized in the ICUs between March, 2020 and July, 2021. Eligible patients were sub-categorized into two groups based on simultaneous co-infection with other respiratory viruses throughout their ICU stay. Influenza A or B, Human Adenovirus (AdV), Human Coronavirus (i.e., 229E, HKU1, NL63, or OC43), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Parainfluenza virus, and Respiratory Syncytial Virus (RSV) were among the respiratory viral infections screened. Patients were followed until discharge from the hospital or in-hospital death. RESULTS: A total of 836 patients were included in the final analysis. Eleven patients (1.3%) were infected concomitantly with other respiratory viruses. Rhinovirus/Enterovirus (38.5%) was the most commonly reported co-infection. No difference was observed between the two groups regarding the 30-day mortality (HR 0.39, 95% CI 0.13, 1.20; p = 0.10). The in-hospital mortality was significantly lower among co-infected patients with other respiratory viruses compared with patients who were infected with COVID-19 alone (HR 0.32 95% CI 0.10, 0.97; p = 0.04). Patients concomitantly infected with other respiratory viruses had longer median mechanical ventilation (MV) duration and hospital length of stay (LOS). CONCLUSION: Critically ill patients with COVID-19 who were concomitantly infected with other respiratory viruses had comparable 30-day mortality to those not concomitantly infected. Further proactive testing and care may be required in the case of co-infection with respiratory viruses and COVID-19. The results of our study need to be confirmed by larger studies.
Subject(s)
COVID-19 , Coinfection , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Viruses , Adult , Humans , Cohort Studies , Respiratory Tract Infections/epidemiology , Retrospective Studies , Coinfection/epidemiology , Hospital Mortality , RhinovirusABSTRACT
In these recent years, the world has witnessed a kind of social exclusion and the inability to communicate directly due to the Corona Virus Covid 19 (COVID-19) pandemic, and the consequent difficulty of communicating with patients with hospitals led to the need to use modern technology to solve and facilitate the problem of people communicating with each other. healthcare has made many remarkable developments through the Internet of things (IoT) and cloud computing to monitor real-time patients' data, which has enabled many patients' lives to be saved. This paper presents the design and implementation of a Private Backend Server Software based on an IoT health monitoring system concerned with emergency medical services utilizing biosensors to detect multi-vital signs of an individual with an ESP32 microcontroller board and IoT cloud. The device displays the vital data, which is then uploaded to a cloud server for storage and analysis over an IoT network. Vital data is received from the cloud server and shown on the IoT medical client dashboard for remote monitoring. The proposed system allows users to ameliorate healthcare jeopardy and minify its costs by re-cording, gathering, sharing, and analyzing vast biodata streams such as Intensive Care Units (ICU) (i.e., temperature, heartbeat rate (HR), Oxygen level (SPO2), etc.), efficiently in real-time. In this proposal, the data is sent from sensors fixed in the patient body to the Web and Mobile App continually in real time for collection and analysis. The system showed impressive performance with an average disparity of less than 1%. body temperature, SPO2, and HR readings were remarkably accurate compared to the CE approval patient monitoring system. In Addition, The system was highly dependable with a success rate for IoT data broadcasts. © 2023,International journal of online and biomedical engineering. All Rights Reserved.
ABSTRACT
Coronavirus disease (COVID-19) is a pandemic disease caused by SARS-COV-2 that primarily attacks the respiratory system of the host. This disease was first reported in early December 2019, and the World Health Organization (WHO) classified the ongoing COVID-19 outbreak as a pandemic disease-causing global public health emergency by mid-January 2020. The human-to-human transmission occurs by droplets, infected hands, or surfaces with an in-cubation time of 2-14 days. It displays signs and symptoms, and if the disease progresses, it leads to death. To avoid symptomatic symptoms or increase infection severity, early diagnosis, quarantine, and supportive care can help to cure the patient infected with COVID-19. Several attempts have been projected for the development of vaccines against COVID-19. As of July 2, 2021, 600 vaccine candidates worldwide were evaluated against SARS-CoV-2, of which 300 have reached the preclinical stage of their development. Presently, Moderna (mRNA-1273), Shenzhen Geno-Immune Medical Institute (LV-SMENP-DC), Shenzhen Geno-Immune Medical Institute (Pathogen specific APC), CanSino Biologicals (Ad5-nCoV), Inovio Pharmaceuti-cals (INO-4800) have plunged into the phase I/II clinical trials (Source: ClinicalTrials.gov web-site;WHO). Scientists are increasingly seeking a key hide behind pathogenic pathways, epide-miological features, and future drug goals, which will lead to the development of successful strategies for prevention and treatment. Based on the current published data, we summarize the structure, life cycle of SARS-CoV-2 and the various product categories available as anti-COVID-19 agents (antiviral), with special emphasis on Chinese herbal medicines, which were licensed as anti-COVID agents by the Chinese Government. Such knowledge can be used as guidelines for COVID-19 clinical therapy. Copyright © 2023 Bentham Science Publishers.
ABSTRACT
Background: Tocilizumab (TCZ) has been proposed as potential rescue therapy for severe COVID-19. No previous study has primarily assessed the role of TCZ in preventing severe COVID-19-related multiorgan dysfunction. Hence, this multicenter cohort study aimed to evaluate the effectiveness of TCZ early use versus standard of care in preventing severe COVID-19-related multiorgan dysfunction in COVID-19 critically ill patients during intensive care unit (ICU) stay. Methods: A multicenter, retrospective cohort study includes critically ill adult patients with COVID-19 admitted to the ICUs. Patients were categorized into two groups, the treatment group includes patients who received early TCZ therapy within 24â hours of ICU admission and the control group includes patients who received standard of care. The primary outcome was the multiorgan dysfunction on day three of the ICU admission. The secondary outcomes were 30-day, and in-hospital mortality, ventilator-free days, hospital length of stay (LOS), ICU LOS, and ICU-related complications. Results: After propensity score matching, 300 patients were included in the analysis based on predefined criteria with a ratio of 1:2. Patients who received TCZ had lower multiorgan dysfunction score on day three of ICU admission compared to the control group (beta coefficient: -0.13, 95% CI: -0.26, -0.01, P-value = 0.04). Moreover, respiratory failure requiring MV was statistically significantly lower in patients who received early TCZ compared to the control group (OR 0.52; 95% CI 0.31, 0.91, P-value = 0.02). The 30-day and in-hospital mortality were significantly lower in patients who received TCZ than those who did not (HR 0.56; 95% CI 0.37, 0.85, P-value = 0 .006 and HR 0.54; 95% CI 0.36, 0.82, P-value = 0.003, respectively). Conclusion: In addition to the mortality benefits associated with early TCZ use within 24â hours of ICU admission, the use of TCZ was associated with a significantly lower multiorgan dysfunction score on day three of ICU admission in critically ill patients with COVID-19.